전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-4 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved3 programs
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Plus Cadonilimab)

Bile Duct Adenocarcinoma Non-Resectable; HER2 Gene Mutation · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BileDuctAdenocarcinomaNon-Resect+2
Trials 6Status Active
AntibodyLimited DatastaleInsel Gruppe AG, University Hos…Phase 2

durvalumab (Imfinzi, Gemcitabin, Cisplatin and Durvalumab)

Bile Duct Cancer · Bile Duct Cancer

#BileDuctCancer#Antibody#Phase2#monoclonal-antibody#Insel
Trials 1Status Recruiting
AntibodyLimited DatastaleNational Cancer Institute (NCI)Phase 2

Varlilumab (Varlilumab)

Metastatic Distal Bile Duct Adenocarcinoma; Metastatic Gallbladder Carcinoma · Metastatic Distal Bile Duct Adenocarcino

#MetastaticDistalBileDuctAdenocar#Antibody#Phase2#monoclonal-antibody#MetastaticGallbladderCarcinoma+1
Trials 1Status Recruiting